Cambridge Investment Research Advisors, Inc. Immunity Bio, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $32.9 Billion
- Q2 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 20,950 shares of IBRX stock, worth $51,327. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,950
Previous 17,950
16.71%
Holding current value
$51,327
Previous $54,000
1.85%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding IBRX
# of Institutions
277Shares Held
121MCall Options Held
2.49MPut Options Held
3.14M-
Vanguard Group Inc Valley Forge, PA21.8MShares$53.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$28 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC8.76MShares$21.5 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.76MShares$19 Million0.36% of portfolio
-
Jane Street Group, LLC New York, NY7.72MShares$18.9 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $981M
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...